DRUG
LY3437943
Administered SC
Status
Completed
Phase
Phase 1
Enrollment
57
Locations
3
Results
Not posted
Publications
0
Study summary
The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.
Interventions
DRUG
Administered SC
DEVICE
Used to administer LY3437943 SC
DEVICE
Used to administer LY3437943 SC
Timeline
First posted
Aug 22, 2023
Study start
Aug 29, 2023
Primary completion
Feb 8, 2024
Study completion
Feb 8, 2024
Results posted
Not reported
Registry updated
Mar 29, 2024
Outcomes
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943
Time frame · Predose up to 43 days postdose
PK: Cmax of LY3437943
PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of LY3437943
Time frame · Predose up to 43 days postdose
PK: AUC\[0-tlast\] of LY3437943
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3437943
Time frame · Predose up to 43 days postdose
PK: AUC(0-∞) of LY3437943
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Healthy males or non-pregnant females as determined by medical history, physical examination, and other screening procedures * Body mass index (BMI) between 18.5 and 32.0 kilograms per meter squared (kg/m²), inclusive * Have clinical laboratory test results, blood pressure and pulse rate that are acceptable for the study * Are agreeable to receiving study treatment by injections under the skin * Males who agree to use highly effective/effective methods of contraception and women not of childbearing potential (postmenopausal or oophorectomized) Exclusion Criteria: * Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study * Smoke more than the equivalent of 10 cigarettes per day * Is a known user of drugs of abuse * Have known allergies to LY3437943 or related compounds
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Qps-Mra, Llc
Miami, Florida, United States
ICON Early Phase Services
San Antonio, Texas, United States
ICON
Salt Lake City, Utah, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.